Vonoprazan/amoxicillin/clarithromycin

Vonoprazan/amoxicillin/clarithromycin
Combination of
VonoprazanPotassium-competitive acid blocker
AmoxicillinBeta-lactam antibiotic
ClarithromycinMacrolide antibiotic
Names
Trade namesVonosap, Voquezna triple pak
Clinical data
Main usesHelicobacter pylori (H. pylori)[1]
Side effectsDiarrhea, vaginal yeast infection, headache, abdominal pain, high blood pressure[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status

Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used to treat Helicobacter pylori (H. pylori) infection.[1] It is taken by mouth.[1]

Common side effects include diarrhea, vaginal yeast infection, headache, abdominal pain, and high blood pressure.[1] Other side effects may include allergic reaction, Clostridioides difficile-associated diarrhea, QT prolongation.[1] Use is generally not recommended in pregnancy.[1] It contains vonoprazan, a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.[1]

The combination was approved for medical use in Japan in 2016,[2] and the United States in 2022.[1] In the United States a course of treatment costs about 860 USD as of 2022.[3] As of 2022 it is not avaliable in Europe or the United Kingdom.[4]

Medical use

Dosage

It is taken as vonoprazan 20 mg plus amoxicillin 1,000 mg plus clarithromycin 500 mg twice per day for two weeks.[1]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 "Voquezna Dual Pak- vonoprazan fumarate and amoxicillin kit Voquezna Triple Pak- vonoprazan fumarate, amoxicillin and clarithromycin kit". DailyMed. 21 June 2022. Archived from the original on 3 July 2022. Retrieved 3 July 2022.
  2. 1 2 "Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan". Takeda. 7 June 2016. Archived from the original on 10 May 2022. Retrieved 9 May 2022.
  3. ↑ "Voquezna Triple Pak Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 12 December 2022.
  4. ↑ "Vonoprazan". SPS - Specialist Pharmacy Service. 10 December 2019. Archived from the original on 25 September 2021. Retrieved 12 December 2022.

Further reading

  • Kajihara Y, Shimoyama T, Mizuki I (February 2017). "Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication". Scand J Gastroenterol. 52 (2): 238–241. doi:10.1080/00365521.2016.1250157. PMID 27806639. S2CID 25801431.
  • Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. (9 July 2019). "A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study". Digestion. 101 (5): 608–614. doi:10.1159/000501608. PMID 31288235. S2CID 195871882.
  • Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, et al. (November 2020). "Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility". J Gastroenterol. 55 (11): 1054–1061. doi:10.1007/s00535-020-01723-6. PMID 32930864. S2CID 221674785.
Identifiers:
  • "Vonoprazan". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 10 May 2022. Retrieved 3 July 2022.
  • "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 3 June 2022. Retrieved 3 July 2022.
  • "Clarithromycin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 22 July 2022. Retrieved 3 July 2022.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.